Medical Marketing and Media - More blockbusters exit as Fosamax, Advair go off-patent
Sunday, November 2nd, 2008MERCK PUT Fosamax (alendronate sodium) and its $3 billion in total 2007 sales in its rear-view mirror last month, following the lapse of patent protection on the osteoporosis drug.
Merck forecast that 2008 sales will decline by at least half that, followed by more attrition later. Fosamax is part of about $20 billion worth of drugs expected to lose patent pr…
